Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

MXCT vs DCTH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DCTH Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 8–2 Matrix Metrics)

DCTH Overall Winner 6-Pillar Tally: MXCT 0 – 6 DCTH Matrix Metrics: MXCT 2 – 8 DCTH

As of Nov 20, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over MaxCyte, Inc. (MXCT) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MXCT carries a Unified Composite Score of 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin), whereas DCTH carries 35.2/100 (SELL) at $18.79 (69.0x Forward P/E, 5.2% operating margin).

  • Composite vs. Pillar Nuance: While MXCT currently prints a higher short-term Unified Composite Score (41.7/100 SELL vs. DCTH 35.2/100 SELL), DCTH captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (5.2% vs. -85.5% operating margin) and revenue trajectory (+70.7% vs. +48.7% YoY).
  • Defensive Composite Rating Caution: Although DCTH compares more favorably head-to-head, both MXCT (41.7/100 SELL) and DCTH (35.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MXCT vs DCTH
MXCT NASDAQ
MaxCyte, Inc. Common Stock
Services-Commercial Physical & Biological Research
$1.37
+7.03% 1D
Market Cap $132.2M
TTM Revenue $34M
Forward P/E N/M
Beta / 30D Vol 1.19β · 96% Vol
Unified Composite Score
41.7 / 100 SELL
Tech 46.0 Fund 52.0 Flow 62.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.1% over 20 days), RSI 55
RSI-14: 55.3 · SMA20: $1.36 · SMA50: $1.25
DCTH NASDAQ Head-to-Head Winner
Delcath Systems Inc
Surgical & Medical Instruments & Apparatus
$18.79
-2.34% 1D
Market Cap $669.3M
TTM Revenue $110M
Forward P/E 69.0x
Beta / 30D Vol 1.57β · 130% Vol
Unified Composite Score
35.2 / 100 SELL
Tech 50.0 Fund 36.0 Flow 70.0 Mom 44.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.0% over 20 days), RSI 58
RSI-14: 57.6 · SMA20: $17.34 · SMA50: $16.22

6-Pillar Scorecard Institutional Category Breakdown (MXCT 0 – 6 DCTH)

Columns: Metric · MXCT · DCTH
1. Valuation Multiples DCTH
Forward P/E N/M 69.0x
Trailing P/E N/M 120.2x
PEG Ratio N/M 1.60x
EV / Revenue 3.9x 5.6x
2. Growth & Scale DCTH
Revenue Growth (YoY) +48.7% +70.7%
Earnings Growth (YoY) +0.0% +750.0%
TTM Revenue (USD) $34M $110M
Market Cap $132.2M $669.3M
3. Profitability & Quality DCTH
Gross Margin 81.0% 87.6%
Operating Margin -85.5% 5.2%
Net Profit Margin -81.4% 6.0%
Return on Equity (ROE) -16.9% 5.4%
4. Balance Sheet & Cash Flow DCTH
Cash Generation (TTM) -$24M $20M
Cash Flow Margin -69.2% 18.3%
Net Cash / Leverage $2.2M Net Debt (0.11x D/E) $53M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DCTH
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 64.8% (26th %ile)
Put/Call OI Skew N/A 0.22x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat DCTH
OpEx & R&D Intensity N/A 82.4% of Rev ($91M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MXCT (2) vs DCTH (8)
Institutional Metric MXCT DCTH Criterion Row Edge
Market Capitalization
Scale
$132.2M $669.3M Larger Scale DCTH
Trailing P/E Ratio
Valuation
N/M 120.2x Lower Multiple DCTH
Forward P/E Ratio
Valuation
N/M 69.0x Lower Multiple DCTH
Revenue Growth (YoY)
Growth
+48.7% +70.7% Higher Growth DCTH
Operating Margin (TTM)
Profitability
-85.5% 5.2% Higher Margin DCTH
Net Profit Margin
Profitability
-81.4% 6.0% Higher Margin DCTH
Return on Equity (ROE)
Capital Efficiency
-16.9% 5.4% Higher ROE DCTH
52-Week Range Position
Momentum
63% ($1–$2) 74% ($8–$23) Stronger Trend DCTH
Beta / 30D Volatility
Risk Regime
1.19β · 96% Vol 1.57β · 130% Vol Lower Realized Risk MXCT
Unified Institutional Score
Composite Signal
41.7 / 100 (SELL) 35.2 / 100 (SELL) Higher Composite MXCT
Trailing 12M Revenue (USD)
Operating Scale
$34M $110M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
81.0% 87.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.9x EV/Rev 1.60x PEG · 5.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$24M ($2.2M Net Debt (0.11x D/E)) $20M ($53M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DCTH +31.59 pp
MXCT: -4.2% · DCTH: +27.39%
3M Horizon DCTH +13.62 pp
MXCT: -1.44% · DCTH: +12.18%
6M Horizon DCTH +38.78 pp
MXCT: +31.73% · DCTH: +70.51%
1Y Horizon DCTH +140.21 pp
MXCT: -19.41% · DCTH: +120.8%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period MXCT Revenue DCTH Revenue MXCT Op. Margin DCTH Op. Margin Margin Leader
FY2015 N/A $0M N/A -870.6% DCTH
FY2019 $10M N/A -93.7% N/A MXCT
FY2020 $20M N/A -71.6% N/A MXCT
FY2021 $20M $0M -84.3% -690.0% MXCT
FY2022 $30M $0M -95.2% -1245.1% MXCT
FY2023 $20M $0M -247.7% -1849.0% MXCT
FY2024 $20M $40M -230.5% -33.4% DCTH
FY2025 $20M $90M -247.6% 0.8% DCTH

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MXCT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MXCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DCTH CONSOLIDATION
70d in phase · OBV DISTRIBUTION
Current IV 64.8%
IV Percentile 26th %ile
Put/Call OI Skew 0.22x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact DCTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MXCT Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $132.2M market capitalization and -85.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DCTH Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $669.3M market capitalization and 5.2% operating margin.
OpEx & R&D Reinvestment 82.4% of Rev ($91M)
90D Engineering Disclosures 0 Published

Investor FAQ MXCT vs DCTH Key Questions & Quantitative Answers

As of Nov 20, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over MaxCyte, Inc. (MXCT) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MXCT carries a Unified Composite Score of 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin), whereas DCTH carries 35.2/100 (SELL) at $18.79 (69.0x Forward P/E, 5.2% operating margin). Composite vs. Pillar Nuance: While MXCT currently prints a higher short-term Unified Composite Score (41.7/100 SELL vs. DCTH 35.2/100 SELL), DCTH captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (5.2% vs. -85.5% operating margin) and revenue trajectory (+70.7% vs. +48.7% YoY). Defensive Composite Rating Caution: Although DCTH compares more favorably head-to-head, both MXCT (41.7/100 SELL) and DCTH (35.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

DCTH leads the Growth & Scale pillar: MXCT posts +48.7% YoY revenue growth and +0.0% YoY earnings growth on $34M TTM revenue (81.0% gross margin, -85.5% operating margin), compared with DCTH at +70.7% YoY revenue growth and +750.0% YoY earnings growth on $110M TTM revenue (87.6% gross margin, 5.2% operating margin). Across the 8-period historical trajectory (FY2015 to FY2025), MXCT cumulative revenue shifted +100.0% while DCTH shifted +125.0%. In operating R&D and SG&A reinvestment, MXCT deploys N/A (0 90-day corporate R&D disclosures) versus 82.4% of Rev ($91M) (0 disclosures) for DCTH.

DCTH screens cheaper on headline valuation multiples. MXCT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (-69.2% FCF margin), whereas DCTH trades at 69.0x Forward P/E, 120.2x Trailing P/E, 1.60x PEG, and 5.6x EV/Revenue (18.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MXCT (-16.9% ROE) versus DCTH (5.4% ROE) capital efficiency.

In options market volatility and institutional positioning, MXCT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 96% Vol realized risk). By comparison, DCTH carries 64.8% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 0.22x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.57β · 130% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.